GlassScriptPhysician profile
Melanie L Sciarra
NPI 1295362333
$469.84
in general payments reported to CMS, 2019-2025
12 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $126 · 2022: $72.84 · 2023: $80.46 · 2024: $83.43 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $271.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $82.38 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.15 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $50.61 | 2021-2024 | Vaxneuvance, Gardasil 9, Gardasil |
| Sanofi-Aventis U.S. LLC | $46.06 | 2025 | |
| Tris Pharma INC | $38.69 | 2021-2024 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $36.54 | 2021 | |
| Glaxosmithkline, LLC. | $33.50 | 2024-2025 | Pediarix, Rotarix, Bexsero |
| Ironshore Pharmaceuticals INC. | $24.43 | 2023 | Jornay Pm |
| Tactile Systems Technology INC | $24.38 | 2025 | Flexitouch Plus, Nimbl |
| Alk-Abello, INC | $20.04 | 2024 | Odactra, Ragwitek, Grastek |
| Sanofi Pasteur INC. | $18.78 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $16.28 | 2023 | Flumist Quadrivalent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Sciarra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.